B of A Securities analyst Jason Zemansky initiates coverage on AlloVir (NASDAQ:ALVR) with a Buy rating and announces Price Target of $17.
B of A Securities Initiates Coverage On AlloVir With Buy Rating, Announces Price Target of $17
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.